May 7, 2026 11:49 AM
Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects
An experimental drug from Revolution Medicines that nearly doubled survival time for patients with advanced pancreas cancer in clinical trials comes with a high rate of mostly low-grade side effects, researchers reported on Wednesday. The report from a first-in-human trial of daraxonrasib is the first peer-reviewed paper to show safety data for what analysts say could become the next standard of care for previously treated metastatic pancreatic cancer. Pancreatic cancer is among the most de...